|
|
Article: Cypress Bioscience Inc. Drug Milnacipran Highlighted in Today's Wall Street Journal Feature on FMS.
- Article from:
- Business Wire
- Article date:
- August 3, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Cypress Bioscience Inc. (NASDAQ:CYPB) drug milnacipran is highlighted in today's Wall Street Journal feature on Fibromyalgia Syndrome (FMS) and potential new treatments entitled "Off-Label Treatments, New Drugs Target Mysterious, Debilitating Fibromyalgia." The review appears in the Personal Journal section of the acclaimed financial daily paper, and provides an update on the drug companies "racing to develop drugs for a highly debilitating disease that has confounded doctors and plagued patients for years," which includes Cypress, Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY).
FMS is characterized by a number of chronic, debilitating symptoms such as ...